Anxiety
  1. Can cannabis prevent Alzheimer’s? (Pub Med)
  2. The therapeutic potential of the endocannabinoid system for Alzheimer’s disease (PubMed)
  3. Endocannabinoid signalling in Alzheimer’s disease (PubMed)
  4. Cannabinoids for the treatment of dementia (PubMed)
  5. The role of the endocannabinoid system in Alzheimer’s disease: facts and hypotheses (PubMed)
  6. The role of phytochemicals in the treatment and prevention of dementia (PubMed)
  7. A molecular link between the active component of marijuana and Alzheimer’s disease pathology (PubMed)
  8. Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic (Pub Med)
Alzheimer’s
  1. Can cannabis prevent Alzheimer’s? (Pub Med)
  2. The therapeutic potential of the endocannabinoid system for Alzheimer’s disease (PubMed)
  3. Endocannabinoid signalling in Alzheimer’s disease (PubMed)
  4. Cannabinoids for the treatment of dementia (PubMed)
  5. The role of the endocannabinoid system in Alzheimer’s disease: facts and hypotheses (PubMed)
  6. The role of phytochemicals in the treatment and prevention of dementia (PubMed)
  7. A molecular link between the active component of marijuana and Alzheimer’s disease pathology (PubMed)
  8. 6. Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic (Pub Med)
Addiction
  1. Impact of Cannabis Use during Stabilization on Methadone Maintenance Treatment (PubMed)
  2. Cannabidiol reduces cigarette consumption in tobacco smokers (PubMed)
  3. Cannabidiol inhibits the reward-facilitating effect of morphine (PubMed)
  4. Dysregulation of cannabinoid CB1 receptor and associated signalling networks in brains of cocaine addicts and cocaine-treated rodents (PubMed)
  5. Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder (ScienceDirect)
  6. Cannabidiol for the treatment of cannabis withdrawal syndrome (PubMed)
  7. Cannabidiol, a non-psychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances (PubMed)
  8. Cannabidiol for the treatment of cannabis withdrawal syndrome (PubMed)
ADD/ADHD
  1. Subtypes of Attention Deficit — Hyperactivity Disorder (ADHD) and cannabis use (PubMed)
  2. Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats (PubMed)
  3. Fitness to drive in spite (because) of THC (PubMed)
AIDS
  1. Cannabidiol inhibits growth and induces programmed cell death in kaposi sarcoma-associated herpes virus-infected endothelium (PubMed)
ALS
  1. Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials (PubMed)
Anorexia
  1. Leptin, ghrelin, and endocannabinoids: Potential therapeutic targets in anorexia nervosa (PubMed)
  2. The role of the endocannabinoid system in eating disorders: Neurochemical and behavioural preclinical evidence (PubMed)
  3. The role of the endocannabinoid system in eating disorders: Neurochemical and behavioural preclinical evidence (PubMed)
Arthritis
  1. Involvement of the endocannabinoid system in osteoarthritis pain (PubMed)
  2. The non-psychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis (PubMed)
  3. Preliminary assessment of the efficacy, tolerability, and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis (PubMed)
  4. The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55 (PubMed)
Atherosclerosis
  1. The potential use of cannabidiol in the therapy of metabolic syndrome (PubMed)
  2. Cannabinoid receptors in atherosclerosis (PubMed)
  3. The role of the endocannabinoid system in atherosclerosis (PubMed)
Asthma
  1. The role of cannabinoids in inflammatory modulation of allergic respiratory disorders, inflammatory pain and ischemic stroke(PubMed)
  2. Activation of cannabinoid receptors prevents antigen-induced asthma-like reaction in guinea pigs (PubMed)
  3. Endogenous cannabinoid receptor agonists inhibit neurogenic inflammations in guinea pig airways (PubMed)
Autism
  1. A novel approach to the symptomatic treatment of autism (Lester Grinspoon M.D., O’Shaughnessy’s)
  2. Cannabinoid receptor type 2, but not type 1, is up regulated in peripheral blood mononuclear cells of children affected by autistic disorders (PubMed)
  3. Mutations found in individuals with autism interfere with endocannabinoid signalling in the brain (Science Daily)
  4. Targeting the endocannabinoid system in the treatment of fragile X syndrome (PubMed)
Bipolar
  1. Cannabinoids in bipolar affective disorder: A review and discussion of their therapeutic potential (PubMed)
  2. Cannabidiol was ineffective for manic episode of bipolar affective disorder (PubMed)
Cancer
  1. Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1 (PubMed)
  2. The inhibitory effects of cannabidiol on systemic malignant tumors (PubMed)
  3. Cannabidiol inhibits angiogenesis by multiple mechanisms (PubMed)
  4. Cannabidiol as potential anticancer drug (PubMed)
  5. Marijuana fights cancer and helps manage side effects (Daily Beast)
  6. Endocannabinoids in endocrine and related tumours (PubMed)
  7. A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells (PubMed)
  8. TRPV2 activation induces apoptotic cell death in human T24 bladder cancer cells: a potential therapeutic target for bladder cancer (PubMed)
  9. Cannabis and Cannabinoids (PDQ®)Laboratory/Animal/Preclinical Studies (Natinal Cancer Institute)
  10. Cannabinoids: potential anticancer agents Manuel Guzmán
Prostate/Colon
  1. Towards the use of non-psychoactive cannabinoids for prostate cancer (PubMed)
  2. Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol (PubMed)
  3. In Vitro Anticancer Activity of Plant-Derived Cannabidiol on Prostate Cancer Cell Lines (Scirp.org)
  4. Chemo-preventive effect of the non-psychotropic Phyto-cannabinoid cannabidiol on experimental colon cancer (PubMed)
Breast Cancer
  1. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy (PubMed)
  2. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis (PubMed)
  3. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma (PubMed)
  4. Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration (PubMed)
Glioblastoma/Brain
  1. Antitumor effects of cannabidiol, a non-psychoactive cannabinoid, on human glioma cell lines (PubMed)
  2. Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival (PubMed)
  3. Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas (PubMed)
  4. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism (PubMed)
Leukemia
  1. Cannabidiol-Induced Apoptosis in Human Leukemia Cells (PubMed)
  2. Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression (PubMed)
Skin Cancer
  1. Anticancer activity of anandamide in human cutaneous melanoma cells (PubMed)
Cancer Related Pain
  1. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial (PubMed)
  2. Multi-centre, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain (PubMed)
  3. Marijuana extract helps prevent chemo pain (UPI)
Chron’s and Stomach Problems
  1. Cannabis finds its way into treatment of Crohn’s disease (PubMed)
  2. Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis (PubMed)
  3. Cannabidiol in inflammatory bowel diseases: a brief overview (PubMed)
  4. Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis (PubMed)
  5. The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis (PubMed)
  6. Cannabinoids and the gut: New developments and emerging concepts (PubMed)
  7. Endocannabinoids and the gastrointestinal tract (PubMed)
  8. Cannabinoids and gastrointestinal motility: Animal and human studies (PubMed)
  9. Hergenrather presents study of Crohn’s patients as a template for clinical research on Cannabis (O’Shaughnessy’s)
Depression
  1. The endocannabinoid system and the treatment of mood and anxiety disorders (PubMed)
  2. Endocannabinoid signaling in the etiology and treatment of major depressive illness (PubMed)
  3. Endocannabinoid system dysfunction in mood and related disorders (PubMed)
  4. Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis Sativa (PubMed)
  5. Antidepressant-like effects of cannabidiol in mice: Possible involvement of 5-HT1A receptors (PubMed)
  6. Serum contents of endocannabinoids are correlated with blood pressure in depressed women (PubMed)
  7. The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants (PubMed)
Diabetes
  1. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice (PubMed)
  2. The impact of marijuana use on glucose, insulin, and insulin resistance among US adults (American Journal of Medicine)
  3. Cannabidiol arrests onset of autoimmune diabetes in NOD mice (PubMed)
  4. The endocannabinoid system in obesity and type 2 diabetes (PubMed)
  5. Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes (PubMed)
  6. The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications (PubMed)
Endocrine Disorders
  1. The role of the endocannabinoid system in the neuroendocrine regulation of energy balance (PubMed)
  2. Endocannabinoid system participates in neuroendocrine control of homeostasis (PubMed)
  3. The emerging role of the endocannabinoid system in endocrine regulation and energy balance (PubMed)
Epilepsy/Seizures
  1. CBD for children with Dravet’s and intractable seizures (Video)
  2. Report of a parent survey of cannabidiol-enriched cannabis use in paediatric treatment-resistant epilepsy (PubMed)
  3. Cannabinoids for epilepsy (PubMed)
  4. Medicinal marijuana stops seizures, brings hope to a little girl (Gazette, Colorado Springs)
  5. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders (PubMed)
  6. From the Editors: Cannabidiol and medical marijuana for the treatment of epilepsy (PubMed)
Fibromyalgia
  1. Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life (PubMed)
  2. Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? (PubMed)
Heart Disease
  1. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signalling pathways in diabetic cardiomyopathy (PubMed)
  2. Is the cardiovascular system a therapeutic target for cannabidiol? (PubMed)
  3. Acute administration of cannabidiol in vivo suppresses ischemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion (PubMed)
  4. Cannabidiol, a non-psychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury (PubMed)
  5. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension (PubMed)
Huntington’s Disease
  1. Cannabinoids: Novel medicines for the treatment of Huntington’s disease (PubMed)
  2. Neuroprotective effects of Phyto cannabinoid-based medicines in experimental models of Huntington’s disease (PubMed)
  3. Prospects for cannabinoid therapies in basal ganglia disorders (PubMed)
Inflammation
  1. The endocannabinoid system: an emerging key player in inflammation (PubMed)
  2. Anti-inflammatory role of cannabidiol and O-1602 in cerulein-induced acute pancreatitis in mice (PubMed)
  3. Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor (PubMed)
  4. Cannabinoids, endocannabinoids, and related analogs in inflammation (PubMed)
  5. Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors (PubMed)
  6. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption (PubMed)
Irritable Bowel
  1. Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis (PubMed)
  2. Cannabidiol in inflammatory bowel diseases: A brief overview (PubMed)
  3. Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? (PubMed)
  4. Endocannabinoids and the gastrointestinal tract (PubMed)
  5. Cannabinoids and the gut: New developments and emerging concepts (PubMed)
Kidney Disease
  1. Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death (PubMed)
Liver Disease
  1. Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis (PubMed)
  2. Therapeutic potential of cannabidiol against ischemia/reperfusion liver injury in rats (PubMed)
  3. The endocannabinoid system and liver diseases (PubMed)
  4. Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice (PubMed)
Metabolic Syndrome
  1. The potential use of cannabidiol in the therapy of metabolic syndrome (PubMed)
  2. Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes (PubMed)
  3. The impact of marijuana use on glucose, insulin, and insulin resistance among US adults (American Journal of Medicine)
Migraine
  1. Effects of anandamide in migraine: data from an animal model (PubMed)
  2. Cannabinoids and hallucinogens for headache (PubMed)
  3. The endocannabinoid system and migraine (PubMed)
  4. Variations in the cannabinoid receptor 1 gene predispose to migraine (PubMed)
Mood Disorders
  1. Effects of cannabidiol (CBD) on regional cerebral blood flow (PubMed)
  2. Endocannabinoid system dysfunction in mood and related disorders (PubMed)
  3. The endocannabinoid system in the regulation of emotions throughout lifespan: A discussion on therapeutic perspectives (PubMed)
  4. The endocannabinoid system and psychiatric disorders (PubMed)
  5. The endocannabinoid system and the treatment of mood and anxiety disorders(PubMed)
  6. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders (PubMed)
Multiple Sclerosis (MS)
  1. THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis (PubMed)
  2. Sativex for the management of multiple sclerosis symptoms (PubMed)
  3. Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity (PubMed)
  4. Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors(PubMed)
  5. Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis (PubMed)
  6. 6. Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain (PubMed)
Nausea
  1. Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus (PubMed)
  2. Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system (PubMed)
  3. Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation (PubMed)
  4. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting (PubMed)
  5. Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats (PubMed)
Neurodegeneration
  1. Cannabidiol for neurodegenerative disorders: Important new clinical applications for this Phyto cannabinoid? (PubMed)
  2. Cannabidiol: A promising drug for neurodegenerative disorders? (PubMed)
  3. Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder (PubMed)
Neuropathic Pain
  1. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain (PubMed)
  2. Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: Mechanisms involved (PubMed)
  3. Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy (PubMed)
  4. Cannabinoids in the management of difficult to treat pain (PubMed)
  5. Marijuana extract helps prevent chemo pain (UPI)
  6. Meta-analysis of cannabis-based treatments for neuropathic and multiple sclerosis-related pain (PubMed)
Obesity
  1. Cannabinol and cannabidiol exert opposing effects on rat feeding patterns (PubMed)
  2. Cannabis and Δ9-tetrahydrocannabinol (THC) for weight loss? (PubMed)
  3. The impact of marijuana use on glucose, insulin, and insulin resistance among US adults (PubMed)
  4. Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk (PubMed)
OCD
  1. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour (PubMed)
Osteporosis
  1. Cannabinoids and bone: Friend or foe? (PubMed)
  2. Cannabinoid receptors as target for treatment of osteoporosis: A tale of two therapies (PubMed)
  3. Cannabinoid receptor type 1 protects against age-related osteoporosis by regulating osteoblast and adipocyte differentiation in marrow stromal cells (PubMed)
  4. Cannabinoids and the skeleton: From marijuana to reversal of bone loss (PubMed)
  5. Endocannabinoids and the regulation of bone metabolism (PubMed)
  6. Cannabinoid receptors and the regulation of bone mass (PubMed)
Parkinsons
  1. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: Importance of antioxidant and cannabinoid receptor-independent properties (PubMed)
  2. Prospects for cannabinoid therapies in basal ganglia disorders (PubMed)
  3. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease (PubMed)
  4. Cannabidiol can improve complex sleep-related behaviours associated with rapideye movement sleep behaviour disorder in Parkinson’s disease patients: a caseseries (PubMed)
  5. Cannabidiol for the treatment of psychosis in Parkinson’s disease (PubMed)
  6. Therapeutic potential of cannabinoids in CNS disease (PubMed)
PTSD
  1. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear (PubMed)
  2. The endocannabinoid system provides an avenue for evidence-based treatment development for PTSD (PubMed)
  3. Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks (PubMed)
  4. Modulation of Fear Memory by Dietary Polyunsaturated Fatty Acids via Cannabinoid Receptors (PubMed)
  5. Cannabinoid modulation of fear extinction brain circuits: A novel target to advance anxiety treatment (PubMed)
  6. Modulation of Fear Memory by Dietary Polyunsaturated Fatty Acids via Cannabinoid Receptors (PubMed)
Schizophrenia
  1. Cannabidiol as a potential treatment for psychosis (PubMed)
  2. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia (PubMed)
  3. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug (PubMed)
  4. Medical use of cannabis. Cannabidiol: A new light for schizophrenia? (PubMed)
  5. Peripheral endocannabinoid system dysregulation in first-episode psychosis (PubMed)
  6. Cannabinoids and schizophrenia: Therapeutic prospects (PubMed)
Skin Conditions
  1. Cannabidiol exerts sebostatic and anti-inflammatory effects on human sebocytes (PubMed)
  2. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis (PubMed)
  3. The endocannabinoid system of the skin in health and disease: Novel perspectives and therapeutic opportunities (PubMed)
  4. Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus (PubMed)
Sleep Disorders
  1. Cannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine (PubMed)
  2. The non-psychoactive Cannabis constituent cannabidiol is a wake-inducing agent (PubMed)
  3. Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats (PubMed)
  4. Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats (PubMed)
Stress
  1. Regulation of endocannabinoid signaling by stress: Implications for stress-related affective disorders (PubMed)
  2. Endogenous cannabinoid signaling is essential for stress adaptation (PubMed)
  3. Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output (PubMed)
  4. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress (PubMed)
  5. Endocannabinoids and stress (PubMed)
  6. Cannabinoid receptor activation prevents the effects of chronic mild stress on emotional learning and LTP in a rat model of depression (PubMed)
Stroke/TBI
  1. Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism (PubMed)
  2. Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism (PubMed)
  3. Cannabidiol, a non-psychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury (PubMed)
  4. Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance (PubMed)

Check if your eligible for Medicinal Cannabis by taking our free eligibility test.

Check eligibility now

For more information please visit our Medicinal Cannabis Info Page

Or check out our collection of clinical studies here

Feel free to contact one of our friendly clinics’ staff by emailing info@nectartek.com.au
or calling us at 1300011232